Immuron (NASDAQ:IMRN) Trading 0.6% Higher – Time to Buy?

Posted by Renee Jackson on Apr 9th, 2026

Shares of Immuron (NASDAQ:IMRN – Get Free Report) shot up 0.6% on Wednesday . The company traded as high as $0.8192 and last traded at $0.7980. 32,786 shares traded hands during trading, an increase of 59% from the average session volume of 20,583 shares. The stock had previously closed at $0.7933.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immuron in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

View Our Latest Stock Report on Immuron

Immuron Stock Performance

The business has a 50-day moving average of $0.79 and a two-hundred day moving average of $1.26.

Immuron (NASDAQ:IMRN – Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.10) EPS for the quarter. The business had revenue of $1.40 million during the quarter. On average, equities analysts expect that Immuron will post -0.02 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immuron stock. Citadel Advisors LLC acquired a new position in Immuron (NASDAQ:IMRN – Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 19,562 shares of the company’s stock, valued at approximately $37,000. Citadel Advisors LLC owned about 0.29% of Immuron as of its most recent SEC filing. Institutional investors own 0.12% of the company’s stock.

Immuron Company Profile

(Get Free Report)

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections.